Gut microbiota and hypertension: From pathogenesis to new therapeutic strategies

Clinics and Research in Hepatology and Gastroenterology

Volumn 42, Issue 2, 2018, Pages 110-117

  Kang, Yongbo ^a   Cai, Yue ^a  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Gut microbiota dysbiosis; Hypertension; Metabolic disorders; Metagenomics; Probiotic therapy

Indexed keywords

PROBIOTIC AGENT;

ACETATE PRODUCING BACTERIA; ACTINOMYCES; BACTERIUM; BACTEROIDETES; BUTYRATE PRODUCING BACTERIA; COPROBACILLUS; ENTEROBACTER; FIRMICUTES; HUMAN; HYPERTENSION; INTESTINE FLORA; KLEBSIELLA; MICROBIAL DIVERSITY; NONHUMAN; PATHOGENESIS; POPULATION ABUNDANCE; PORPHYROMONAS; PREVOTELLA; SHORT SURVEY; SPECIES COMPOSITION; SPECIES RICHNESS; SYSTOLIC BLOOD PRESSURE; VEILLONELLACEAE; MICROBIOLOGY;

GASTROINTESTINAL MICROBIOME; HUMANS; HYPERTENSION; PROBIOTICS;

EID: 85032907688     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2017.09.006     Document Type: Short Survey

References (57)

1. Kearney, P.M., Whelton, M., Reynolds, K., et al. Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005), 217–223.
2. WHO, Prevention of cardiovascular diseases. 2007, World Health Organization, Geneva.
3. Guptamalhotra, M., Banker, A., Shete, S., et al. Essential hypertension vs. secondary hypertension among children. Am J Hypertens 28 (2015), 73–80.
4. Judd, E., Calhoun, D.A., Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis 22 (2015), 116–122.
5. Caulfield, M., Lavender, P., Farrall, M., et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 330 (1994), 1629–1633.
6. Levy, D., Ehret, G.B., Rice, K., et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 41 (2009), 677–687.
7. Benjafield, A.V., Jeyasingam, C.L., Nyholt, D.R., et al. G-protein β3 subunit gene (GNB3) variant in causation of essential hypertension. Hypertension 32 (1999), 1094–1097.
8. Benjafield, A.V., Morris, B.J., Association analyses of endothelial nitric oxide synthase gene polymorphisms in essential hypertension. Am J Hypertens 13 (2000), 994–998.
9. Solak, Y., Afsar, B., Vaziri, N.D., et al. Hypertension as an autoimmune and inflammatory disease. Hypertens Res 39 (2016), 567–573.
10. Guarner, F., Malagelada, J.R., Gut flora in health and disease. Lancet 361 (2003), 512–519.
11. Salminen, S., Bouley, C., Boutronruault, M.C., et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 80:Suppl. 1 (1998), S147–S171.
12. Sun, J.X.W., Wang, G., The role of intestinal microflora and its possible mechanisms in hypertension [J]. Lipid Cardiovasc Res 2:1 (2016), 08–16.
13. Afsar, B., Vaziri, N.D., Aslan, G., et al. Gut hormones and gut microbiota: implications for kidney function and hypertension. J Am Soc Hypertens, 1933.
14. Daliri, E.B., Lee, B.H., Oh, D.H., Current perspectives on antihypertensive probiotics. Prob Antimicrob Prot, 2016, 1–11.
15. Miremadi, F., Sherkat, F., Stojanovska, L., Hypocholesterolaemic effect and anti-hypertensive properties of probiotics and prebiotics: a review. J Funct Foods 25 (2016), 497–510.
16. James, P.A., Oparil, S., Carter, B.L., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
17. Newman, J.H., Trembath, R.C., Morse, J.A., et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol, 43, 2004, 33S.
18. Hengstenberg, C., Association between a polymorphism in the G protein β3 subunit gene (GNB3) with arterial hypertension but not with myocardial infarction. Cardiovasc Res, 49, 2001, 820.
19. Yannoutsos, A., Levy, B.I., Safar, M.E., et al. Pathophysiology of hypertension: interactions between macro- and microvascular alterations through endothelial dysfunction. J Hypertens 32 (2014), 216–224.
20. Kudryashova, T.V., Goncharov, D.A., Ziai, H., et al. Nox4 regulates mTORC2-Akt signaling and vascular smooth muscle cell remodeling in pulmonary hypertension. Am J Respir Crit Care Med, 189, 2014, A3632.
21. Majumder, K., Wu, J., Molecular targets of antihypertensive peptides: understanding the mechanisms of action based on the pathophysiology of hypertension. Int J Mol Sci 16 (2014), 256–283.
22. Jose, P.A., Raj, D., Gut microbiota in hypertension. Curr Opin Nephrol Hypertens 24 (2015), 403–409.
23. Niranjana, N., Pluznick, J.L., From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Cell Physiol, 307, 2014, C979.
24. Tang, W.H.W., Wang, Z., Kennedy, D.J., et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circul Res 116 (2015), 448–455.
25. Hartiala, J., Bennett, B.J., Tang, W.H., et al. Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscl Thromb Vasc Biol, 34, 2014, 1307.
26. Furness, J.B., Rivera, L.R., Cho, H.J., et al. The gut as a sensory organ. Nat Rev Gastroenterol Hepatol 10 (2013), 729–740.
27. Pluznick, J.L., Protzko, R.J., Gevorgyan, H., et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A, 110, 2013, 4410.
28. Pluznick, J., A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microb 5 (2013), 202–207.
29. Schiffrin, E.L., Immune mechanisms in hypertension and vascular injury. Clin Sci, 126, 2014, 267.
30. Cotillard, A., Kennedy, S.P., Kong, L.C., et al. Dietary intervention impact on gut microbial gene richness. Nature 500 (2013), 585–588.
31. Yang, T., Santisteban, M.M., Rodriguez, V., et al. Gut dysbiosis is linked to hypertension. Hypertension, 65, 2015, 1331.
32. Durgan, D.J., Ganesh, B.P., Cope, J.L., et al. Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension, 67, 2016, 469.
33. Adnan, S., Nelson, J.W., Ajami, N.J., et al. Alterations in the gut microbiota can elicit hypertension in rats. Physiol Genom 49 (2017), 96–104.
34. Mell, B., Jala, V.R., Mathew, A.V., et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genom 47 (2015), 187–197.
35. Li, J., Zhao, F., Wang, Y., et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome, 5, 2017, 14.
36. Machiels, K., Joossens, M., Sabino, J., et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut, 63, 2014, 1275.
37. Bryant, M.P., Small, N., The anaerobic monotrichous butyric acid-producing curved rod-shaped bacteria of the rumen. J Bacteriol 72 (1956), 16–21.
38. Pinzone, M.R., Celesia, B.M., Microbial translocation in chronic liver diseases. Int J Microbiol, 2012, 2012, 694629.
39. Zeller, G., Tap, J., Voigt, A.Y., et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol, 10, 2014, 766.
40. Feng, Q., Liang, S., Jia, H., et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun, 6, 2015, 6528.
41. Zhang, X., Zhang, D., Jia, H., et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med, 21, 2015, 895.
42. Kumar, S., Arya, P., Mukherjee, C., et al. Novel aromatic ester from Piper longum and its analogues inhibit expression of cell adhesion molecules on endothelial cells. Biochemistry 44 (2005), 15944–15952.
43. Wang, W., Zheng, J.P., Zhu, S.X., et al. Carbocisteine attenuates hydrogen peroxide-induced inflammatory injury in A549 cells via NF-κB and ERK1/2 MAPK pathways. Int Immunopharmacol 24 (2015), 306–313.
44. Kang, Y., Cai, Y., Zhang, X., et al. Altered gut microbiota in RA: implications for treatment. Z Fur Rheumatol, 2016, 1–7.
45. Kang, Y., Zhang, X., Cai, Y., et al. Gut microbiota and metabolic disease: from pathogenesis to new therapeutic strategies. Rev Med Microbiol 27 (2016), 141–152.
46. Kang, Y.B., Cai, Y., Zhang, H., Gut microbiota and allergy/asthma: from pathogenesis to new therapeutic strategies. Allergol Immunopathol 45 (2017), 305–309.
47. Brisbin, J.T., Gong, J., Parvizi, P., et al. Effects of lactobacilli on cytokine expression by chicken spleen and cecal tonsil cells. Clin Vacc Immunol, 17, 2010, 1337.
48. Ou, C.C., Lin, S.L., Tsai, J.J., et al. Heat-killed lactic acid bacteria enhance immunomodulatory potential by skewing the immune response toward Th1 polarization. J Food Sci 76 (2011), M260–M267.
49. Sierra, S., Laravilloslada, F., Sempere, L., et al. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe, 16, 2010, 195.
50. Lee, J.H., Valeriano, V.D., Shin, Y.R., et al. Genome sequence of Lactobacillus mucosae LM1, isolated from piglet feces. J Bacteriol, 194, 2012, 4766.
51. Seppo, L., Jauhiainen, T.T., Korpela, R., A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 77 (2003), 326–330.
52. Ahrén, I.L., Xu, J., Onning, G., et al. Antihypertensive activity of blueberries fermented by Lactobacillus plantarum DSM 15313 and effects on the gut microbiota in healthy rats. Clin Nutr, 34, 2014, 719.
53. Yang, G., Jiang, Y., Yang, W., et al. Effective treatment of hypertension by recombinant Lactobacillus plantarum expressing angiotensin converting enzyme inhibitory peptide. Microbial Cell Fact, 14, 2015, 202.
54. Aoyagi, Y., Park, S., Matsubara, S., et al. Habitual intake of fermented milk products containing Lactobacillus casei strain Shirota and a reduced risk of hypertension in older people. Beneficial Microb 8 (2017), 23–29.
55. Staff, T.P.O., Correction: probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system. Plos One, 9, 2014, e97458.
56. Thushara, R.M., Gangadaran, S., Solati, Z., et al. Cardiovascular benefits of probiotics: a review of experimental and clinical studies. Food Funct 7 (2016), 632–642.
57. Gómezguzmán, M., Toral, M., Romero, M., et al. Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats. Mol Nutr Food Res 59 (2015), 2326–2336.